Kidney Disease

 
ADA 2021: Baseline Insulin Use May not Impact Benefits of Finerenone in Patients with CKD, T2D
June 29, 2021

ADA 2021. A subgroup analysis of the FIDELIO-DKD trial showed that finerenone use was beneficial regardless of baseline insulin use among patients with T2D and CKD.

ADA 2021: Use of Dapagliflozin Decreases Risk of Diabetes in Patients with CKD
June 29, 2021

ADA 2021. Dapagliflozin was found to reduce type 2 diabetes incidence among patients with chronic kidney disease in a prespecified analysis of the DAPA-CKD trial.

FDA Approves Dapagliflozin to Treat Chronic Kidney Disease in Adults at Risk of Progression, Regardless of Diabetes Status
May 03, 2021

Dapagliflozin is the first SGLT-2 inhibitor to receive FDA approval for the treatment of CKD, regardless of diabetes status.

SGLT2 Inhibitors Enter Vast Treatment Void for High-risk CKD Patients
December 08, 2020

Patients with chronic kidney disease have had no treatment options to slow the certain progression to renal failure. Enter SGLT2 inhibitors. A key clinical trial investigator explains.

DAPA-CKD Investigator: "PCPs Should be First-line Prescribers of SGLT2 Inhibitors"
December 03, 2020

Primary care clinicians should be the first to prescribe SGLT2 inhibitors for many reasons, as explained by Prof Jonathan McMurray in this Patient Care interview.

Professor John McMurray Highlights DAPA-CKD Trial Outcomes
December 02, 2020

DAPA-CKD investigator Professor John McMurray details the trial and renal and cardiovascular outcomes for Patient Care Online.

Kidney Week: Dapagliflozin Renoprotective, Cardioprotective in CKD Patients
October 26, 2020

Dapagliflozin is renoprotective and cardioprotective in chronic kidney disease patients, suggests a secondary analysis of the DAPA-CKD trial presented at Kidney Week 2020.